肝动脉栓塞化疗联合中药治疗原发性肝癌的疗效观察.doc

肝动脉栓塞化疗联合中药治疗原发性肝癌的疗效观察【摘要】目的评价肝动脉栓塞化疗(transcatheterhepaticarterialchemoembolization,TACE)联合中药治疗在肝癌中临床价值。方法我科自2005年5月一2007年10月,共62例肝癌患者接受肝动脉栓塞化疗。所有患者被随机分为两组,其中研究组38例,在介入治疗的同期或前后服用中药治疗,对照组24例,仅接受肝动脉栓塞化疗。所有患者均接受2个或2个以上疗程的TACE术,术后定期随访。根据实体瘤的临床疗效评价标准,2个疗程TACE治疗后进行临床疗效评价。结果2个疗程TACE术后1个月复查CT评价临床疗效,完全缓解(CR)3例,部分缓解(PR)43例,稳定(SD)12例,进展(PD)4例,其中研究组CR2例,PR30例,SD4例,PD2例,对照组CR1例,PR13例,SD8例,PD2例。,%(42/62),%(28/38)%(14/24)o治疗过程中大多数毒性都是轻微、一过性的,随访过程屮并未发现严重不良事件。在III〜IV度的毒性方而,研究组显著低于对照组。结论肝动脉栓塞化疗联合中药治疗肝癌能显著提高临床疗效,同吋降低不良反应的发生率及程度。【关键词】原发性肝癌;肝动脉栓塞化疗;binedwithChinesemateriamedicaforPrimaryLiverCancer[Abstract]ObjectiveToinvestigatetheclinicalvalueoftranscatheterhepaticarterialchemoembolization(,atotalof62patientswithprimarylivercancerwerereceivedTACE・ binedwithChinesemateriamedica(experimentalgroup),whileanother24patientswerereceivedTACEalone(controlgroup)・ordingtoresponseevaluationcriteriainsolidtumors・pleteresponse(CR)wasachievedin3of62evaluablepatients,43hadpartialresponse(PR),12hadstabledisease(SD)and4hadprogressivedisease(PD)・Inexperimentalgroup,CRwasseenin2patients,PRin30patients,SDin4patientsandPDin2patients・Whi1eincontrolgroup,CRwasseenin1patient,PRin13patients,SDin8patientsandPDin2patients・Withamedianfollow—,1-% (42/62),% (28/38)% (14/24)incontrolgroup・Duringthefollow-upperiods,mosttoxicitywaslow-gradeandtransientandclinicallysignificantadverseeventwasnotobserved・Thegrade3~・[Keywords]Primary1ivercancer;transcatheterhepaticarterialchemoembolization;Chinesemateriamedica冃前肝癌首选的治疗方法仍是手术切除,但由于肝癌起病隐匿,患者早期常无症状,而多数患者确诊为肝癌时已为屮晚期,丧失了手术机会,能手术切除者仅占10%〜15%o肝动脉栓塞化疗(TACE)是丧失手术机会或无法手术切除的中、晚期肝癌患者首选治疗方法。中药因能减毒增效,提高肝癌介入治疗效果,